CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $25.85M, above the global median of $16.24M
- PositionProfit margin is 101.6%, higher than 95% of its Biotechnology peers (median -45.7%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
754.90MUSDvs all stocks (USD)
Trailing P/E
6.35xvs Biotechnology peers
Revenue (TTM)
122.29MUSDvs all stocks (USD)
Profit Margin
101.58%vs Biotechnology peers
Beta
0.8520xvs all stocks
52-Week Change
8.87%vs all stocks
Market Capitalization
754.90MUSDvs all stocks (USD)
Enterprise Value
555.43MUSDvs all stocks (USD)
Trailing P/E
6.35xvs Biotechnology peers
Forward P/E
10.69xvs Biotechnology peers
PEG Ratio
-0.0056xvs Biotechnology peers
Price to Sales (TTM)
6.17xvs Biotechnology peers
Price to Book (MRQ)
3.67xvs Biotechnology peers
Enterprise to Revenue
4.54xvs Biotechnology peers
Enterprise to EBITDA
43.62xvs Biotechnology peers
Gross Margin
94.76%vs Biotechnology peers
Profit Margin
101.58%vs Biotechnology peers
Operating Margin
24.38%vs Biotechnology peers
Return on Assets (TTM)
2.76%vs Biotechnology peers
Return on Equity (TTM)
100.65%vs Biotechnology peers
Revenue (TTM)
122.29MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.17USDUpdated Jul 19, 2026Quarterly Revenue Growth
77.50%vs Biotechnology peers
Gross Profit (TTM)
105.25MUSDvs all stocks (USD)
EBITDA (TTM)
6.77MUSDvs all stocks (USD)
Net Income (TTM)
117.00MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
77.54%vs Biotechnology peers
Operating Cash Flow (TTM)
12.77MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
25.85MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
106.47MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
16.48MUSDFY2025 · Dec 31, 2025Gross Profit
89.99MUSDFY2025 · Dec 31, 2025Operating Income
-4.23MUSDvs all stocks (USD)
Pre-tax Income
86.68MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.45MUSDFY2025 · Dec 31, 2025Net Income
83.23MUSDFY2025 · Dec 31, 2025EBIT
94.66MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
6.77MUSDFY2025 · Dec 31, 2025Research & Development
12.74MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
77.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.95MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.98MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.40USDFY2025 · Dec 31, 2025EPS (Diluted)
1.35USDFY2025 · Dec 31, 2025Basic Shares Outstanding
55.31MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
55.31MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
83.23MUSDFY2025 · Dec 31, 2025Operating Cash Flow
98.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
98.32MUSDDerived from operating cash flow minus capital expenditure. This filing charges 4.05M of depreciation against 387K of capital expenditure, and its own free-cash-flow line reads -2.43M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
62.41MUSDFY2025 · Dec 31, 2025Interest Paid
5.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
83.23MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.05MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
3.45MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.63MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.33MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.98MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-387.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-309.99MUSDFY2025 · Dec 31, 2025Sale of Investments
328.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
18.13MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-372.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
8.27MUSDFY2025 · Dec 31, 2025Shares Outstanding
59.11MSharesUpdated Jul 19, 2026Float Shares
54.93MSharesUpdated Jul 19, 2026Shares Short
6.49MSharesUpdated Jul 19, 2026Short Ratio
3.32daysvs all stocks
Short % of Shares Outstanding
11.11%vs all stocks
% Held by Insiders
1.28%vs all stocks
% Held by Institutions
73.39%vs all stocks
Total Cash (MRQ)
200.62MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.39USDUpdated Jul 19, 2026Total Debt (MRQ)
1.15MUSDvs all stocks (USD)
Current Ratio (MRQ)
4.89xvs Biotechnology peers
Book Value per Share (MRQ)
3.48USDUpdated Jul 19, 2026Total Assets
284.73MUSDvs all stocks (USD)
Total Current Assets
223.01MUSDFY2025 · Dec 31, 2025Total Liabilities
130.07MUSDFY2025 · Dec 31, 2025Total Non-current Assets
61.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
90.80MUSDFY2025 · Dec 31, 2025Total Current Liabilities
39.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
62.41MUSDFY2025 · Dec 31, 2025Other Short-term Investments
128.60MUSDFY2025 · Dec 31, 2025Accounts Receivable
9.88MUSDFY2025 · Dec 31, 2025Inventory
1.74MUSDFY2025 · Dec 31, 2025Accounts Payable
2.48MUSDFY2025 · Dec 31, 2025Short-term Debt
419.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.55MUSDFY2025 · Dec 31, 2025Long-term Debt
62.79MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
11.41MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-422.06MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
154.66MUSDvs all stocks (USD)
Treasury Stock
10.98MUSDFY2025 · Dec 31, 202552-Week Low
7.16USDUpdated Jul 19, 202652-Week High
15.04USDUpdated Jul 19, 202652-Week Change
8.87%vs all stocks
Beta
0.8520xvs all stocks
50-Day MA
12.24USDUpdated Jul 19, 2026200-Day MA
10.08USDUpdated Jul 19, 2026Avg 10-Day Volume
1.37MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.73MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
2.01USDUpdated Jul 19, 2026Other Income / Expense
91.94MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 101.6%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 1.02Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 100.7%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 1.01Industry median: -0.22Industry P95: 0.23Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 117,001,000Operating Cash Flow (USD, TTM): 12,766,000
Financial Health
Altman Z-Score 3.65: safe zoneNotable
Altman Z-Score: 3.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $25.85M, above the global median of $16.24MNotable
Levered free cash flow (USD): 25,852,250Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bright Minds Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Si-Bone Inc.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
MPC Container Ships ASA
4 interpretationsMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Global Ship Lease Inc.
4 interpretationsMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Krystal Biotech Inc.
4 interpretationsMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated